HMG-CoA Reductase Inhibitors: Class Overview Monograph

Mechanism of Action

Statins competitively inhibit 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, blocking the conversion of HMG-CoA to mevalonate. This is the rate-limiting step in the mevalonate pathway, which produces cholesterol in the liver. Reduced intracellular cholesterol triggers upregulation of hepatocyte LDL receptors, increasing clearance of circulating LDL-C from plasma 1.

Pleiotropic Effects Beyond LDL Lowering

The mevalonate pathway also generates isoprenoid intermediates (farnesyl pyrophosphate, geranylgeranyl pyrophosphate) that prenylate small GTPases such as Rho, Ras, and Rac. By reducing isoprenoid availability, statins exert anti-inflammatory, antithrombotic, and endothelial-stabilizing effects independent of LDL-C reduction. Clinical markers of these effects include reduced high-sensitivity C-reactive protein (hsCRP). In the JUPITER trial (N=17,802), rosuvastatin 20 mg lowered hsCRP by 37% alongside a 50% reduction in LDL-C 2. Whether these pleiotropic properties contribute meaningfully to cardiovascular outcomes beyond LDL lowering remains debated, though the consistency of benefit across statin trials supports their clinical relevance 3.

Individual Agents and Potency Tiers

The 2018 AHA/ACC guideline classifies statin therapy into three intensity tiers based on expected percentage reduction in LDL-C 4.

High-Intensity Statins (LDL-C Reduction ≥50%)

Atorvastatin 40-80 mg and rosuvastatin 20-40 mg. These are the agents recommended for secondary prevention in patients with clinical ASCVD, for primary prevention in patients with LDL-C ≥190 mg/dL, and for diabetic patients aged 40-75 with elevated risk. Rosuvastatin 40 mg produces the greatest LDL-C lowering of any available statin monotherapy, with mean reductions of 55-63% 5.

Moderate-Intensity Statins (LDL-C Reduction 30-49%)

Atorvastatin 10-20 mg, rosuvastatin 5-10 mg, simvastatin 20-40 mg, pravastatin 40-80 mg, lovastatin 40 mg, fluvastatin 80 mg (XL), and pitavastatin 1-4 mg. The 2018 guideline states: "For patients in whom high-intensity statin therapy would otherwise be recommended, if high-intensity therapy is not tolerated, moderate-intensity therapy should be used as the maximum tolerated statin dose" 4.

Low-Intensity Statins (LDL-C Reduction <30%)

Simvastatin 10 mg, pravastatin 10-20 mg, lovastatin 20 mg, and fluvastatin 20-40 mg. These are rarely a therapeutic target. Clinicians may encounter patients on low-intensity doses from prior prescribers, warranting reassessment against current guidelines.

Pharmacokinetics

Pharmacokinetic differences between statins guide drug selection, particularly in patients on complex regimens or with hepatic/renal impairment 6.

Absorption and Prodrug Status

Lovastatin and simvastatin are administered as inactive lactone prodrugs requiring hepatic hydrolysis to their active hydroxy-acid forms. All other statins are administered in their active acid forms. Lovastatin absorption increases roughly 50% when taken with food; atorvastatin, rosuvastatin, and pitavastatin can be taken without regard to meals.

Metabolism and CYP Involvement

This is the most clinically consequential pharmacokinetic variable. Atorvastatin, lovastatin, and simvastatin undergo extensive CYP3A4 metabolism, creating a high interaction burden with CYP3A4 inhibitors (azole antifungals, macrolide antibiotics, protease inhibitors, diltiazem, verapamil, grapefruit juice in large quantities). Fluvastatin is metabolized primarily by CYP2C9. Pitavastatin undergoes minimal CYP metabolism (primarily glucuronidation via UGT1A3 and UGT2B7), making it the statin with the fewest CYP-mediated interactions 7. Pravastatin is not significantly metabolized by CYP enzymes. Rosuvastatin has limited CYP2C9 involvement (approximately 10% of elimination).

Hydrophilicity

Pravastatin and rosuvastatin are hydrophilic, resulting in lower passive diffusion into extrahepatic tissues and, theoretically, fewer muscle-related side effects. Simvastatin, lovastatin, fluvastatin, atorvastatin, and pitavastatin are lipophilic.

Renal Elimination

Rosuvastatin has the highest renal excretion fraction (~28%). Dose adjustment is recommended in severe renal impairment (CrCl <30 mL/min), with a starting dose of 5 mg and a maximum of 10 mg for the 40 mg formulation. Atorvastatin has negligible renal elimination and requires no dose adjustment for kidney disease 6.

Landmark Clinical Trial Evidence

The evidence base for statins spans over three decades and dozens of randomized controlled trials. The Cholesterol Treatment Trialists' (CTT) Collaboration meta-analysis of 26 trials (N=170,000) demonstrated a 22% relative reduction in major vascular events per 1.0 mmol/L (38.7 mg/dL) reduction in LDL-C, a finding consistent across subgroups defined by age, sex, baseline risk, and diabetes status 8.

Secondary Prevention Trials

The Scandinavian Simvastatin Survival Study (4S; N=4,444) was the first to demonstrate that statin therapy reduced all-cause mortality. Simvastatin 20-40 mg reduced total mortality by 30% (RR 0.70, 95% CI 0.58-0.85) over 5.4 years in patients with prior MI or angina and total cholesterol 213-309 mg/dL 9. The PROVE IT-TIMI 22 trial (N=4,162) compared atorvastatin 80 mg to pravastatin 40 mg in acute coronary syndrome patients, finding a 16% relative risk reduction in the composite primary endpoint favoring intensive therapy (P=0.005), establishing the "lower is better" principle for LDL-C 10.

Primary Prevention Trials

WOSCOPS (N=6,595) demonstrated that pravastatin 40 mg reduced nonfatal MI and coronary death by 31% in hypercholesterolemic men without prior MI 11. The JUPITER trial (N=17,802) enrolled patients with LDL-C <130 mg/dL but hsCRP ≥2 mg/L, showing rosuvastatin 20 mg reduced the composite primary endpoint by 44% (HR 0.56, 95% CI 0.46-0.69) 2. This trial expanded the eligible population for statin therapy beyond traditional LDL-C thresholds.

Intensive vs. Moderate Therapy

The TNT trial (N=10,001) randomized stable coronary disease patients to atorvastatin 80 mg vs. 10 mg. High-intensity therapy reduced major cardiovascular events by 22% (HR 0.78, 95% CI 0.69-0.89; P<0.001), with mean LDL-C of 77 mg/dL vs. 101 mg/dL 12. Dr. John LaRosa, the lead investigator, noted: "These findings show that intensive lipid lowering with 80 mg of atorvastatin per day in patients with stable coronary heart disease is associated with significant clinical benefit" 12.

Safety and Adverse Effects

Statins are among the most widely prescribed drug classes globally, with a generally favorable safety profile supported by decades of post-marketing surveillance 13.

Musculoskeletal Complaints

Myalgia without CK elevation is reported by 5-10% of statin-treated patients in observational studies, though the SAMSON trial (N=60) demonstrated that two-thirds of statin-attributed symptoms also occurred during placebo periods, indicating a substantial nocebo contribution 14. True statin myopathy with CK elevation above 10 times ULN occurs in approximately 1 per 10,000 patient-years. Rhabdomyolysis is exceedingly rare (1-3 per 100,000 patient-years) and is most associated with simvastatin 80 mg, which the FDA restricted in 2011 to patients who have tolerated it for 12 months without myopathy 15.

Hepatotoxicity

Transaminase elevations (ALT/AST) exceeding 3 times ULN occur in <1% of patients on moderate-intensity therapy and ~2-3% on atorvastatin 80 mg. The 2018 AHA/ACC guideline recommends checking hepatic function at baseline and as clinically indicated thereafter, rather than routine serial monitoring 4. Clinically significant hepatotoxicity is rare, and chronic stable liver disease (including NAFLD/MASLD) is not a contraindication to statin use.

New-Onset Diabetes

The CTT meta-analysis confirmed a modest increase in diabetes incidence, with approximately one additional case of diabetes per 1,000 patient-years of statin therapy, predominantly in patients with pre-existing metabolic risk factors 8. The cardiovascular benefit far outweighs this risk. A 2010 meta-analysis of 13 trials (N=91,140) found an odds ratio of 1.09 (95% CI 1.02-1.17) for new-onset diabetes with statin therapy 16. High-intensity regimens carry a higher risk than moderate-intensity regimens.

Cognitive Concerns

The FDA added a label statement in 2012 regarding post-marketing reports of reversible cognitive impairment. Large trials and systematic reviews, including the Heart Protection Study (N=20,536), have not confirmed a causal association between statin use and cognitive decline 17.

Drug-Drug Interactions

Clinically significant interactions center on CYP3A4 (for atorvastatin, simvastatin, lovastatin) and OATP1B1/OATP1B3 hepatic uptake transporters (all statins, but rosuvastatin and pitavastatin are particularly dependent on these transporters) 7.

CYP3A4-Mediated Interactions

Strong CYP3A4 inhibitors (itraconazole, ketoconazole, clarithromycin, HIV protease inhibitors, cobicistat) are contraindicated with simvastatin and lovastatin. Atorvastatin requires dose limitation (do not exceed 20 mg) with these agents. Moderate CYP3A4 inhibitors (diltiazem, verapamil, erythromycin, fluconazole) require simvastatin dose caps of 10-20 mg. Grapefruit juice in quantities exceeding one quart daily should be avoided with CYP3A4-metabolized statins. Alternative agents in complex regimens: pitavastatin, pravastatin, or rosuvastatin.

Transporter-Mediated Interactions

Cyclosporine inhibits OATP1B1, CYP3A4, and P-glycoprotein. It is contraindicated with simvastatin, lovastatin, and pitavastatin, and requires dose limits for atorvastatin (10 mg), rosuvastatin (5 mg), and pravastatin (20 mg). Gemfibrozil inhibits OATP1B1 and glucuronidation, raising statin exposure substantially; it is contraindicated with simvastatin and should be avoided with most statins in favor of fenofibrate when combination lipid therapy is needed.

Warfarin

Rosuvastatin, fluvastatin, and (to a lesser extent) simvastatin can increase warfarin's INR. Monitor INR closely when initiating or changing statin doses in warfarin-treated patients.

Prescribing Considerations and Patient Selection

The 2018 AHA/ACC guideline identifies four statin-benefit groups 4:

The Four Statin-Benefit Groups

1. Clinical ASCVD (secondary prevention): high-intensity statin for patients aged ≤75 years; moderate-to-high intensity for those over 75 years.
2. Severe hypercholesterolemia (LDL-C ≥190 mg/dL): high-intensity statin without requiring risk calculation.
3. Diabetes mellitus, age 40-75: moderate-intensity statin baseline; high-intensity if 10-year ASCVD risk ≥7.5%.
4. Primary prevention, age 40-75, LDL-C 70-189 mg/dL, 10-year ASCVD risk ≥7.5%: moderate-to-high intensity statin after clinician-patient risk discussion.

Statin Intolerance Management

True complete statin intolerance (inability to tolerate any statin at any dose) affects approximately 2-3% of patients. Before labeling a patient statin-intolerant, the AHA recommends trying at least two different statins, including a rechallenge with a low dose of a high-potency statin. Dr. Steven Nissen of the Cleveland Clinic has stated: "Many patients who think they cannot tolerate statins can actually do well on a different statin or a lower dose" 18. Alternate-day dosing of rosuvastatin (5-10 mg every other day) or pitavastatin (2 mg daily) are evidence-supported strategies for intolerant patients 18.

Monitoring

Baseline lipid panel and hepatic function panel before starting therapy. Repeat fasting lipid panel at 4-12 weeks after initiation or dose change. CK measurement only if symptomatic. No routine CK or LFT screening during maintenance therapy unless symptoms develop.

Special Populations

Chronic Kidney Disease

Atorvastatin is preferred in moderate-to-severe CKD because of its lack of renal elimination. The SHARP trial (N=9,270) demonstrated that simvastatin 20 mg plus ezetimibe 10 mg reduced major atherosclerotic events by 17% in CKD patients not yet on dialysis 19. Statins should not be initiated in patients already receiving maintenance dialysis, per KDIGO 2013 guidelines, though they may be continued if already prescribed 20.

Older Adults

For secondary prevention, statin therapy continues to reduce events in patients aged 75 and older, as supported by the CTT subgroup analysis. For primary prevention in adults over 75, shared decision-making is recommended, incorporating life expectancy, polypharmacy, and patient preference.

Pregnancy and Lactation

All statins are contraindicated in pregnancy and during breastfeeding. Cholesterol is required for fetal development, and case reports of congenital anomalies exist, though a causal link is unproven. Women of childbearing potential should use effective contraception during therapy 15.

Patients requiring lipid-lowering therapy who are planning pregnancy should discontinue statins at least 1-3 months before conception. Bile acid sequestrants (cholestyramine, colesevelam) can be used during pregnancy if needed.